What we do Morepen Laboratories Limited is an Indian pharmaceutical company producing APIs, formulations, and home diagnostic medical devices, serving global markets with a diversified healthcare portfolio. |
Founded in 1,984 |
Market share Leader in anti-allergic APIs; strong global presence with growing market share in antihistamines and cardio-vascular drugs; medical devices with expanding footprint. |
Problem solved Provides affordable, quality pharmaceuticals and diagnostics for chronic and lifestyle diseases, addressing health monitoring and treatment needs globally. |
Top clients or who we serve B2B and B2C clients including pharmaceutical companies, healthcare providers, and end consumers worldwide, notably in India, Europe, USA, and Asia-Pacific. |
Key management Sushil Suri (Chairman & Managing Director), Sanjay Suri (Whole Time Director), Ajay Kumar Sharma (CFO), Vipul Kumar Srivastava (Company Secretary). |
Our journey and innovations Established 1984; first API USFDA approval; expanded product range; filed 14 patents; diversified into diagnostics and personal care; consistently enhanced capacities. |
Where we operate India, USA, Europe, Asia-Pacific, Middle East, South America with significant export revenues. |
Top products or what we offer APIs (Loratadine, Montelukast, Atorvastatin), formulations, OTC products, home diagnostics (glucometers, BP monitors), and emerging orthopaedic devices. |
Top brands Saltum, Saltumax, Cefpopen, Burnol (#1 OTC burn relief), Dr. Morepen diagnostics (glucose, BP monitors), Montelest antihistamines. |
Raw materials needed Chemical intermediates for bulk drug (API) synthesis; components for diagnostic devices including electronics and plastics. |
Raw materials supplier Global and domestic suppliers specialized in pharmaceutical raw materials and medical device components. |
Recurring vs cyclical contribution Revenue driven mainly by recurring API and device sales with growing cyclical contributions from formulations and new product launches. |
Our industry position Among top API exporters from India, significant share in anti-asthmatic drugs; growing presence in home diagnostics and OTC healthcare products. |
Financial highlights Consolidated revenue ~Rs.1829 Crores (FY25); PAT Rs.118 Crores; 7.37% revenue growth; EBITDA margin improved to 10.52%. |
Geographical revenue split India ~60%, Rest of World including USA, Europe, Asia ~40% of consolidated revenues. |
Order book - |
Whats driving growth Growth fueled by expanding diagnostics devices, OTC portfolio, export market penetration, new API molecules, and strategic business realignment. |
Our future plans Expand medical devices manufacturing; enhance API portfolio; grow orthopaedic product line; build export capacity; innovation in diagnostics. |
Our green promise Committed to sustainable manufacturing practices and energy conservation as per regulatory norms. |
Our people and values 18% manpower growth; focus on inclusive work culture and employee development; adherence to ethical business practices. |
Key challenges ahead Competition from global generics; regulatory compliance; pricing pressures in domestic market; supply chain optimization. |
Interesting facts USFDA approved production of best-selling global anti-allergy drug Loratadine; developed unique amorphous APIs under patent. |
Risks and strategy Mitigates regulatory and market risks via diversified product portfolio, geographical spread, R&D innovation, and strategic partnerships. |
